image: Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is proud to be listed. Other honorees include internet giants like Alibaba, ByteDance, Meta, and Microsoft; leading companies in the chip industry such as AMD and NVIDIA; and AI emerging stars like Hugging Face and OpenAI.
Credit: Fortune 50 AI Innovators
Over 700 days after the debut of ChatGPT, the phenomenal AI application, industries have completed their first attempts to understand and embrace AI innovations, implementing real-scale deployments of AI technologies in 2024. The era of AI is indeed ushering in transformative changes.
On November 20th, the renowned business magazine Fortune released its 2024 Fortune 50 AI Innovators list, highlighting the AI companies leading in the new phase of AI technology applications. Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, is proud to be listed. Other honorees include internet giants like Alibaba, ByteDance, Meta, and Microsoft; leading companies in the chip industry such as AMD and NVIDIA; and AI emerging stars like Hugging Face and OpenAI.
Following its first release in 2023, the Fortune 50 AI Innovators list continues to focus on players with the most traction and cutting-edge AI products. Spanning various fields from healthcare to software services, the carefully selected companies are using AI technology to transform industry developments, solve complex challenges, enhance work efficiency, and make AI accessible for global business.
Among all industries, healthcare is especially expected to benefit from AI breakthroughs, with challenges including high costs, complex processes, and workforce shortages. As predicted by McKinsey, AI could create $370 billion in value for healthcare by accelerating drug discovery and development and promoting precisely targeted personalized treatments.
In 2016, Insilico first described the concept of using generative AI for the design of novel molecules in a peer-reviewed journal, which laid the foundation for the commercially available Pharma.AI platform. Since then, Insilico keeps integrating technical breakthroughs into Pharma.AI platform, which is currently a generative AI-powered solution spanning across biology, chemistry, medicine development and science research. Powered by Pharma.AI, Insilico has nominated 20 preclinical candidates in its comprehensive portfolio of over 30 assets since 2021 and has received IND clearance for 10 molecules.
In early 2024, Insilico published a Nature Biotechnology paper presenting the entire R&D journey from AI algorithms to Phase II clinical trials of ISM001-055, the company's lead drug pipeline with AI-discovered target and AI-designed structure. Following that, Insilico has recently announced positive preliminary results from a Phase IIa trial (NCT05938920), where ISM001-055 showed favorable safety and tolerability across all dose levels, as well as dose-dependent response in forced vital capacity (FVC), after only 12 weeks of dosage.
About Insilico Medicine
Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.